



National Viral Hepatitis Action Plan

Local Health Departments and Hepatitis C: Webcast 1.2

Presented by:

Corinna Dan, RN, MPH

Office of HIV/AIDS and Infectious Disease Policy
Department of Health and Human Services



National Viral Hepatitis Action Plan

Updated 2014-2016

Corinna Dan, RN, MPH

*Office of HIV/AIDS and Infectious Disease Policy
Department of Health and Human Services*

Impact



2013 Viral Hepatitis Epidemiology, U.S.

| | Hepatitis A (HAV) | Hepatitis B (HBV) | Hepatitis C (HCV) |
|--|--|--|--|
| Acute cases <i>(annual estimated)</i> | 3,473 <i>14% ↑ in reported cases compared to 2012</i> | 19,764 <i>5.4% ↑ in reported cases compared to 2012</i> | 29,718 151.5% ↑ <i>in reported cases from 2010 to 2013</i> |
| Chronic infections <i>(prevalent cases)</i> | | 700,000 – 1.4 million | 2.7-3.9 million |
| Est. perinatal <i>(annual estimated)</i> | | 800 – 1,000 | ? |
| Deaths (2013) <i>(annual reported)</i> | 80 | 1,873 | 19,368 |

*Between 45% to 65% of chronically infected persons are unaware of their infection status.

<http://www.cdc.gov/hepatitis/Statistics/2013Surveillance/index.htm>

Response



Cross-Agency Collaboration – Viral Hepatitis Implementation Group (VHIG)



Office of the
Assistant Secretary for Health



The Office of the National Coordinator for
Health Information Technology



Members without logos: Office of HIV/AIDS and Infectious Disease Policy
Regional Health Administrators

Affordable Care Act Opportunities

- **Elimination of pre-existing condition restrictions**
- **Expanded access to health insurance**
- **Preventive health care coverage**
 - **Screening**
 - USPSTF Grade A or B
 - **Vaccination**
 - ACIP recommended

CDC Home
Centers for Disease Control and Prevention
CDC 24/7: Saving Lives. Protecting People.™

A-Z Index: [A](#) [B](#) [C](#) [D](#) [E](#) [F](#) [G](#) [H](#) [I](#) [J](#) [K](#) [L](#) [M](#) [N](#) [O](#) [P](#) [Q](#) [R](#) [S](#) [T](#) [U](#) [V](#) [W](#) [X](#) [Y](#) [Z](#)

Prevention of HIV/AIDS, Viral Hepatitis, STDs, and TB Through Health Care

USHHS > Prevention Through Health Care > Preventive Service Tables

Recommend Tweet Share

[For Questions About Content Type/Label/Contact Us](#)

Viral Hepatitis Preventive Services

| Preventive Service | Recommending Authority (authorized under Section 1002 of the Patient Protection and Affordable Care Act) | Eligible Population |
|-------------------------|--|---|
| Hepatitis A Vaccination | Advisory Committee on Immunization Practices (ACIP) (Recommendations issued and adopted by the Director of the Centers for Disease Control and Prevention May 2008) | Routine for children, for increased risk for any person with no immunity* (See MMWR Through Act Immunization: The Advisory Committee on Immunization Practices) |
| Hepatitis B Vaccination | Advisory Committee on Immunization Practices (ACIP) (Recommendations issued and adopted by the Director of the Centers for Disease Control and Prevention December 2005) | Universal vaccination for all children, who were not pregnant and being at risk (HBV) infect unvaccinated infection, or protection from (See MMWR Immunization: Infectious Disease Immunization: Adolescents: Compliance to Eliminate B Virus Infection Part 2: Immunization Discussion) |
| Hepatitis B Testing | USPSTF (Grade "B" recommendation issued May 2014) | Screening for infection in high-risk populations* |



HCV Therapy Has Undergone a Revolution

AMERICAN ASSOCIATION FOR
THE STUDY OF LIVER DISEASES



Recommendations for
Testing, Managing, and
Treating Hepatitis C



U.S. Food and Drug Administration
Protecting and Promoting *Your* Health

[Home](#) [Food](#) [Drugs](#) [Medical Devices](#) [Radiation-Emitting Products](#) [Vaccines, Blood & Biologics](#) [Animal & Veterinary](#)

News & Events

[Home](#) [News & Events](#) [Newsroom](#) [Press Announcements](#)

FDA News Release

FDA approves first combination pill to treat hepatitis C

For Immediate
Release

October 10, 2014

Release


[Español](#)

The U.S. Food and Drug Administration today approved Harvoni (ledipasvir and sofosbuvir) to treat chronic hepatitis C virus (HCV) genotype 1 infection.

Harvoni is the first combination pill approved to treat chronic HCV genotype 1 infection. It is also the first approved regimen that does not require administration with interferon or ribavirin, two FDA-approved drugs also used to treat HCV infection.

Breakthrough Therapy Approvals

Gaps in the U.S. HCV Continuum of Care



* Chronic HCV-Infected; N=3,500,000.

† Calculated as estimated number chronic HCV-infected (3,500,000) x estimated percentage diagnosed and aware of their infection (49.8%); n=1,743,000.

‡ Calculated as estimated number diagnosed and aware (1,743,000) x estimated percentage with access to outpatient care (86.9%); n=1,514,667.

§ Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage HCV RNA confirmed (62.9%); n=952,726.

|| Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage who underwent liver biopsy (38.4%); n=581,632.

¶ Calculated as estimated number with access to outpatient care (1,514,667) x estimated percentage prescribed HCV treatment (36.7%); n=555,883.

** Calculated as estimated number prescribed HCV treatment (555,883) x estimated percentage who achieved SVR (58.8%); n=326,859.

Note: Only non-VA studies are included in the above HCV treatment cascade.

Yehia et al, PLOS One, 2014

Importance of Stakeholders





The Vital Role of Stakeholders

The updated VHAP underscores that its national goals cannot be achieved through federal action alone.


Active involvement, and innovation, from a broad mix of nonfederal stakeholders from various sectors, both public and private, is essential.

The VHAP provides a framework and focus around which all stakeholders can engage to strengthen the nation's response to viral hepatitis.

Health Department Roles



U.S. Viral Hepatitis Action Plan and Stakeholders' Workbook




Examples of Opportunities for Health Departments:

- Help disseminate professional training tools and materials.
- Use CDC's hepatitis campaign materials to help spread the word about the importance of getting tested for viral hepatitis.
- Hold regular hepatitis testing events, and participate in National Testing Day on May 19th.
- Continue to build coalitions to expand the ability to reach populations most impacted by viral hepatitis.
- Support surveillance projects and epidemiological investigations to help understand the characteristics and needs of the emerging hepatitis C epidemic among people who inject drugs.
- Develop more detailed information about population-specific health disparities in viral hepatitis prevention, diagnosis, care, and treatment.

Visit <http://aids.gov/hepatitis>

Know More Hepatitis



Materials available at www.cdc.gov/hepatitis

Courtesy of CDC DVH Education, Training, & Communications Team



We Have the Tools!

▲ Centers for Disease Control and Prevention

- Educational materials, training resources, and guidelines
- www.cdc.gov/hepatitis

▲ U.S. Department of Health and Human Services

- Viral Hepatitis Action Plan, Stakeholders' Workbook, updates & reports, and blogs
- www.AIDS.gov/hepatitis

▲ Veterans Administration

- Patient and Provider education and tools
- <http://www.hepatitis.va.gov/>

▲ American Association for the Study of Liver Disease

- Primary healthcare provider training on viral hepatitis
- <http://www.aasld.org/act-first-free-online-cme-course-primary-care-providers>



Be the Action in the Viral Hepatitis Action Plan!

Thank you!

Corinna Dan, RN, MPH

Corinna.Dan@hhs.gov



Local Health Departments and Hepatitis C

NACCHO Educational Series

- Webcast 1.1 Hepatitis C: Where Are We Now?
- Webcast 1.2 The National Viral Hepatitis Action Plan
- Webcast 1.3 Viral Hepatitis C Testing Recommendations for Persons Born 1945-1965
- Webcast 1.4 Leveraging Partnerships to Address Hepatitis C: Philadelphia's Model

All materials available at www.naccho.org/hepatitisc